For instance, anti-PD-1 mAbs bind to PD-1 receptors on T-cells, while anti-PD-L1 mAbs target PD-L1 ligands present on cancer cells or other cells in the tumor microenvironment (Li et al., 2021[54]). This evidence concerns the gene PDCD1 and neoplasm.